Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
Tuesday, September 2, 2025 1 min read
Key Takeaway: Structure Therapeutics Inc. (NASDAQ: GPCR) will participate in two healthcare investor conferences in September 2025. The company is dedicated to developing novel oral small molecule therapeutics for metabolic diseases, particularly obesity. Webcasts of the events will be available on their website, ensuring accessibility for interested investors.
Price reaction · baseline $19.3 (2025-08-29 close) · hit pre-market · clean, no other GPCR news in the window
day 0 close · peak
+4%
Market Sentiment Analysis
POSITIVE FACTORS
Structure Therapeutics is participating in two healthcare conferences.
The company is focused on developing innovative treatments for metabolic diseases.
Management's engagement in investor conferences indicates proactive investor relations.
Full Press Release Details
SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two upcoming healthcare conferences in September.
Cantor Global Healthcare Conference
Format:
Fireside chat and 1x1 meetings
Date/time:
Wednesday, September 3 at 3:55 p.m. ET
Location:
New York, NY
Morgan Stanley 23rd Annual Global Healthcare Conference
About Structure TherapeuticsStructure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visitwww.structuretx.com.